BioSpace News Archive

Drug Development

Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy

Biomerica Inc. (NASDAQ:BMRA) today announced that the first patient has been enrolled in the randomized, double-blind, placebo-controlled, clinical trial of its new InFoods® diagnostic-guided therapy (DGT) to alleviate Irritable Bowel Syndrome (IBS) symptoms.

July 5, 2018
·
5 min read
Drug Development

Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial

Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant

July 5, 2018
·
8 min read
Policy

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Flex Pharma, Inc.

Federman & Sherwood announces that on June 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Flex Pharma, Inc.

July 5, 2018
·
1 min read
Lexington Biosciences Concludes Initial HeartSentry Clinical Study--Company prepares for multicenter pivotal clinical study

Lexington Biosciences, Inc. is pleased to announce the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo Clinical Research.

July 5, 2018
·
5 min read
Deals

RENNOVA HEALTH ANNOUNCES CONFIRMATION FROM TENNESSEE DEPARTMENT OF HEALTH THAT A NEW LICENSE NUMBER HAS BEEN ISSUED DUE TO THE CHANGE OF OWNERSHIP FOR JAMESTOWN TN, MEDICAL CENTER.

Rennova Health, Inc. announces that it has received confirmation from the Tennessee Department of Health that they have completed the change of ownership (CHOW) process and issued a license number to Jamestown TN Medical Center, Inc.

July 5, 2018
·
3 min read
Drug Development

ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.

July 5, 2018
·
6 min read
Pharm Country

Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients

Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies

July 5, 2018
·
7 min read
Biotech Bay

Amfora Unveils Broad Initiative to Develop Crops with Enhanced Protein Content for Food and Feed

Amfora Inc. unveiled a major new program to develop crops with enhanced protein.

July 5, 2018
·
3 min read
Drug Development

Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy

Corvus Pharmaceuticals, Inc. announced publication of results of preclinical studies of CPI-444

July 5, 2018
·
6 min read
Pharm Country

AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands

AXIM® Biotechnologies, Inc. announced that the company will be attending as a sponsor at the 28th Annual International Cannabinoid Research Society (ICRS) Symposium

July 5, 2018
·
3 min read